


Details:
The net proceeds will be used to advance OLT1177 (dapansutrile) into later stage clinical development. Dapansutrile is an investigational small molecule, that specifically binds to and blocks NLRP3, the sensor molecule integral in the formation of the NLRP3 inflammasome.
Lead Product(s): Dapansutrile
Therapeutic Area: Rheumatology Product Name: OLT1177
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sanders Morris Harris
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 23, 2023